BIOTRON LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.054 AUD | -1.82% |
|
-3.57% | -44.33% |
| Apr. 05 | Biotron Meets Primary Objectives of Phase Two HIV Trial; Shares Surge 25% | MT |
| Feb. 26 | Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.56M 1.04M | Sales 2023 | 1.43M 952K | Capitalization | 23.45M 15.6M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -1.33M | Net income 2023 | -3M -2M | EV / Sales 2022 | 26.4 x |
| Net cash position 2022 | 1.66M 1.11M | Net cash position 2023 | 3.94M 2.62M | EV / Sales 2023 | 13.6 x |
| P/E ratio 2022 |
-15.4
x | P/E ratio 2023 |
-6.11
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 80.28% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.82% | ||
| 1 week | -3.57% | ||
| Current month | -5.26% | ||
| 1 month | -20.59% | ||
| 3 months | -40.66% | ||
| 6 months | -40.66% | ||
| Current year | -44.33% |
1 week
0.05
0.06
1 month
0.050.07
Current year
0.050.12
1 year
0.020.13
3 years
0.020.13
5 years
0.020.19
10 years
0.010.45
| Managers | Title | Age | Since |
|---|---|---|---|
Michelle Miller
CEO | Chief Executive Officer | - | 02-06-20 |
Stephen Becker
CTO | Chief Tech/Sci/R&D Officer | - | 20-07-16 |
| Corporate Secretary | 67 | 99-02-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Thomas
BRD | Director/Board Member | 79 | 12-03-06 |
Michael Hoy
CHM | Chairman | 75 | 00-02-06 |
Michelle Miller
CEO | Chief Executive Officer | - | 02-06-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 0.054 | -1.82% | 36 864 |
| 24-05-20 | 0.055 | 0.00% | 535,594 |
| 24-05-17 | 0.055 | -3.51% | 874,418 |
| 24-05-16 | 0.057 | 0.00% | 99,980 |
| 24-05-15 | 0.057 | +1.79% | 233,541 |
Delayed Quote Australian S.E., May 20, 2024 at 09:55 pm EDT
More quotes
Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Companyâs clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -44.33% | 33.17M | |
| +9.58% | 115B | |
| +12.41% | 106B | |
| -2.59% | 21.96B | |
| -12.38% | 21.87B | |
| -5.29% | 19.21B | |
| -3.35% | 18.08B | |
| -38.57% | 17.71B | |
| +7.51% | 14.32B | |
| +35.67% | 12.42B |
- Stock Market
- Equities
- BIT Stock
